Medicare Enrolled
Dr. Michael Vincent Tablang, M.D.
Infectious Disease · Crestview, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Tablang from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Tablang?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Tablang
Dr. Michael Vincent Tablang is an infectious disease specialist in Crestview, FL, with 18 years of NPI registration. Based on federal Medicare data, Dr. Tablang performed 716,905 Medicare services across 3,284 unique beneficiaries.
Between the years covered by Open Payments, Dr. Tablang received a total of $3,453 from 27 pharmaceutical and/or device companies across 178 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in infectious disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Tablang is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 1% volume in FL
$3,453 industry payments
Florida License Status
FL DOH · MQA1
Active license
None
Board action on record
0
Recent admin complaints
| Profession | License # | Status | Expires | Board Action |
|---|---|---|---|---|
| Medical Doctor | 138845 | Clear | January 31, 2027 | — |
Data from Florida Department of Health Medical Quality Assurance.
License records are public under Chapter 119, Florida Statutes.
Verify directly on FL DOH →
Medicare Practice Summary
Medicare Utilization ↗716,905
Medicare services
Top 1% in FL for infectious disease
3,284
Unique beneficiaries
$3
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~39,828 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Daptomycin antibiotic injection | 566,961 | $0 | $0 |
| Injection, omadacycline, 1 mg | 103,601 | $3 | $8 |
| Oritavancin antibiotic injection, 10 mg This procedure involves the administration of a 10 mg dose of oritavancin, an antibiotic medication, via injection. |
23,880 | $32 | $109 |
| Dalbavancin injection, 5 mg An injection of the antibiotic dalbavancin, administered in a 5 mg dose. |
3,600 | $12 | $42 |
| Injection, cefepime hydrochloride, 500 mg | 2,523 | $1 | $4 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
2,503 | $0 | $12 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
2,092 | $48 | $177 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,843 | $98 | $352 |
| Ertapenem sodium injection, 500 mg An injection of ertapenem sodium, an antibiotic medication, administered at a dose of 500 mg. |
1,808 | $11 | $63 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
1,714 | $93 | $333 |
| Denosumab injection (Prolia/Xgeva) | 1,200 | $19 | $69 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
1,080 | $22 | $83 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
836 | $168 | $509 |
| Skin and tissue removal, 20 sq cm or less This procedure involves the surgical excision of skin and underlying tissue from an area measuring 20 square centimeters or smaller. |
778 | $99 | $362 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
514 | $62 | $189 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
484 | $15 | $55 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
401 | $136 | $490 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
204 | $17 | $42 |
| Vein wound compression bandage application, lower leg, ankle, and foot Application of compression bandages to the lower leg, ankle, and foot to manage vein-related wounds. |
181 | $67 | $289 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
150 | $128 | $473 |
| Wound tissue removal, 20 sq cm or less This procedure involves the removal of tissue from a wound area measuring 20 square centimeters or less. |
149 | $76 | $231 |
| Anti-nausea injection (ondansetron/Zofran) | 82 | $0 | $0 |
| Additional skin and tissue removal, per 20 sq cm This code covers the removal of skin and tissue for each additional 20 square centimeters or less beyond the initial procedure. |
63 | $32 | $114 |
| Strapping, unna boot | 63 | $52 | $236 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
48 | $69 | $270 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
44 | $11 | $37 |
| New patient office visit, complex (60-74 min) | 34 | $120 | $474 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
31 | $12 | $51 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
22 | $121 | $428 |
| Home health plan of care certification Certification by a physician or allowed practitioner for Medicare-covered home health services under a home health plan of care. This includes contacting the home health agency and reviewing reports of patient status required by physicians. |
16 | $40 | $156 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.5% high complexity
98.5% medium
1.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,453
Total received (2019-2024)
Avg $575/year across 6 years
Top 27% in FL for infectious disease
27
Companies
178
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,453 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$413
2023
$640
2022
$675
2021
$867
2020
$422
2019
$436
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Insmed, Inc.
$432
ViiV Healthcare Company
$423
AbbVie Inc.
$363
Organogenesis Inc.
$326
Horizon Therapeutics plc
$313
Paratek Pharmaceuticals, Inc.
$292
GRT US Holding, Inc.
$217
Allergan Inc.
$185
Merck Sharp & Dohme LLC
$136
ABBVIE INC.
$120
Gilead Sciences, Inc.
$90
Melinta Therapeutics, LLC
$89
Merck Sharp & Dohme Corporation
$82
Allergan, Inc.
$53
MIMEDX Group, Inc.
$51
AbbVie, Inc.
$45
Averitas Pharma Inc.
$37
ConvaTec Inc.
$33
Urgo Medical North America, LLC
$30
Melinta Therapeutics, Inc.
$23
AngioDynamics, Inc.
$22
Philips Electronics North America Corporation
$22
Amgen Inc.
$17
Janssen Biotech, Inc.
$15
KCI USA, Inc.
$14
Ferring Pharmaceuticals Inc.
$13
TETRAPHASE PHARMACEUTICALS, INC.
$11
Top 3 companies account for 35.2% of total payments
Associated products mentioned in payments ›
(8874) inCourage · APRETUDE · AVYCAZ · Arikayce · Baxdela · BioFlo · CABENUVA · DALVANCE · DIFICID · DOVATO · DuraMax · EVENITY · INNOVAMATRIX AC · ISENTRESS · KRYSTEXXA · Kimyrsa · MAVYRET · Mavyret · NUZYRA · Orbactiv · PIFELTRO · Puraply · QUTENZA · Qutenza · REBYOTA · SYMTUZA · TEFLARO · TEPEZZA · V.A.C. DERMATAC · VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP · Xerava · ZERBAXA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $0 per 100 Medicare services performed
Geographic Context
Infectious diseases within 10 mi
6
Per 100K population
2.8
County median income
$79,097
Nearest hospital
NORTH OKALOOSA MEDICAL CENTER
7.4 mi
7.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Tablang is a mixed practice specialist, with above-average Medicare volume (top 1% in FL), with low-engagement industry engagement, with 18 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Tablang experienced with daptomycin antibiotic injection?
Based on Medicare claims data, Dr. Tablang performed 566,961 daptomycin antibiotic injection services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Tablang receive payments from pharmaceutical companies?
Yes. Dr. Tablang received a total of $3,453 from 27 companies across 178 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Tablang's costs compare to other infectious diseases in Crestview?
Dr. Tablang's average Medicare payment per service is $3. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Tablang) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Infectious Diseases in Crestview
Browse infectious diseases in Crestview ranked by procedure volume and transparency data.
Highest volume
Top Infectious Diseases in FL
Infectious diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Infectious Diseases in FL
Which FL infectious diseases receive the most from drug and device companies.
By company
Insmed, Inc. Payments to Doctors
See all physicians who received payments from Insmed, Inc.
By company
ViiV Healthcare Company Payments to Doctors
See all physicians who received payments from ViiV Healthcare Company.
By company
AbbVie Inc. Payments to Doctors
See all physicians who received payments from AbbVie Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology